Building Supply Chain Resiliency through Responsible Sourcing

When the world went into lockdown in early 2020, manufacturing of critical ingredients came to a standstill, and companies were forced to re-evaluate their supply chains. 

Forward to 2021, and companies are still dealing with port closures and shipments of expensive ingredients sat in a backlog, many are faced with the decision of either waiting weeks for deliveries or the faster, yet more expensive domestic production to ensure the continuity of supply of essential medicines.  

Discussion Points: 
 

• Creating a geographically robust supply chain is critical for reducing drug shortages,  
• Ensuring essential medicines security through public-private partnerships  
• Risk management and the pivot to regional manufacturing hubs 
  

In Partnership with PSCI